IXICO PLC's (LON:IXI) Lammert Albers talks to Proactive London about landing three new contracts, with three different customers in the area of Alzheimer's disease.
Albers talks through each of the projects, which includes a phase I study, an expansion deal for a phase II clinical assessment, and it will deploy its expertise on an open-label extension phase III trial.
Albers also highlights the importance of the CTAD and the Aducanumab advisory committee meeting this Friday, which will take place virtually this year.
